
Arvinas Inc
ARVNHealthcare|Biotechnology|USA
$8.28
-0.27 (-3.10%)
Tangible Book
$6.00
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
116.12,
62.96,
80.79,
130.45,
190.7
],
"ebit_estimate": [
-204.64,
-275.96,
-256.18,
-225.89,
-161.97
],
"ebitda_estimate": [
-182.09,
-253.97,
-202.85,
null,
null
],
"net_income_estimate": [
-177.86,
-249.98,
-230.68,
-207.75,
-171.41
],
"per_share_eps_estimate": [
-2.88,
-3.6,
-3.19,
-2.32,
-1.51
],
"eps_nri_estimate": [
-2.88,
-3.46,
-3.07,
-2.32,
-1.51
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
4.2,
4,
-0.31,
null,
null
],
"pretax_income_estimate": [
-185.4,
-250.36,
-236.67,
-211.34,
-147.41
],
"operating_cash_flow_per_share_estimate": [
-1.92,
-3.8,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
-35.86,
-72.43,
-194.35,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
100,
100
],
"operating_cash_flow_estimate": [
-122.88,
-243.2,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": -37.09,
"long_term_revenue_growth_rate_mean": "-33.96",
"future_per_share_eps_estimate_growth": -39.28,
"future_eps_nri_estimate_growth": -37.09,
"future_revenue_estimate_growth": -33.96,
"future_ebit_estimate_growth": -29.85,
"future_ebitda_estimate_growth": -22.41,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -41.73,
"future_pretax_income_estimate_growth": -42.41,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": -125.95,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
35.95,
29.98,
27.79,
10.74,
11.56,
12.06,
14.02
],
"ebit_estimate": [
-27.67,
-55.66,
-61.13,
-66.03,
-66.26,
-66.5,
-66.58
],
"ebitda_estimate": [
-0.86,
-60.61,
-75.59,
null,
null,
null,
null
],
"net_income_estimate": [
-29.67,
-50.34,
-54.08,
-59.66,
-62.46,
-62.94,
-63.46
],
"per_share_eps_estimate": [
-0.41,
-0.77,
-0.81,
-0.96,
-0.97,
-0.92,
-0.88
],
"eps_nri_estimate": [
-0.42,
-0.77,
-0.79,
-0.96,
-0.97,
-0.92,
-0.88
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-39.39,
-47.58,
-51.44,
-59.66,
-62.46,
-62.94,
-63.46
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
-42.08,
-35.2,
-41.07,
null,
null,
null,
null
],
"gross_margin_estimate": [
100,
100,
100,
100,
100,
100,
100
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": -37.09,
"long_term_revenue_growth_rate_mean": "-33.96",
"future_per_share_eps_estimate_growth": -39.28,
"future_eps_nri_estimate_growth": -37.09,
"future_revenue_estimate_growth": -33.96,
"future_ebit_estimate_growth": -29.85,
"future_ebitda_estimate_growth": -22.41,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -41.73,
"future_pretax_income_estimate_growth": -42.41,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": -125.95,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}